Search
Stoke Therapeutics Inc
STOKAdd to Watchlist
29.320USD
+0.020+0.07%
Close 07-27 16:00（ET）Quotes delayed by 15 min
1.73BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-27The current earnings forecast score of Stoke Therapeutics Inc is 9.00, ranking 16 out of 386 in the Biotechnology & Medical Research industry. The average price target is 33.50, with a high of 39.00 and a low of 24.00.
Analyst Rating
Based on
13
analysts
Buy
Current Rating
45.818
Target Price
+56.38%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Stoke Therapeutics Inc
STOK
13
Beigene Ltd
ONC
28
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Stoke Therapeutics Inc's expected revenue for the next quarter?
Stoke Therapeutics Inc's expected revenue is 6.04M.
What is Stoke Therapeutics Inc's price target?
Analysts forecast that Stoke Therapeutics Inc's price target is USD 33.50, with the highest forecast at USD 39.00 and the lowest forecast at USD 24.00.
How have Stoke Therapeutics IncSTOK's recent earnings per share performed?
The market expectation was USD -0.79, while Stoke Therapeutics IncSTOK's earnings per share (EPS) for the previous quarter was USD -0.98. EPS for the next quarter is expected at USD -0.80.
What is the analyst rating for Stoke Therapeutics Inc?
Based on the ratings of Stoke Therapeutics Inc's stock from 13 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.